Drug Trial Radar · NCT03995108
Efficacy and Safety Study of Mavorixafor in Participants With Warts, Hypogammaglobulinemia, Infections, and Myelokathexis (WHIM) Syndrome
Last checked: Nov 19, 2026Latest source record: Jul 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
31
Actual
Start
Oct 24, 2019
Primary completion
Dec 23, 2025
Study completion Dec 23, 2025
Sponsor
- Lead sponsor
- X4 PharmaceuticalsIndustry
- Sponsor type
- Industry
- First posted
- Jun 21, 2019
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study has a double-blind, Randomized Placebo-Controlled Period and an Open-Label Period. The primary objective of the Randomized Placebo-Controlled Period is to demonstrate the efficacy of mavorixafor in participants with WHIM syndrome as assessed by increasing levels of circulating neutrophils compared with placebo, and relative to a clinically meaningful threshold. The primary objective of the Open-Label Period is to evaluate the safety and tolerability of mavorixafor in participants with WHIM syndrome. Participants are allowed to continue treatment in the Open-Label Period, if regionally applicable, until mavorixafor becomes commercially available, or until the study is terminated by the Sponsor.
Conditions
- WHIM Syndrome
Interventions
MavorixaforDrug
Mavorixafor provided as 100 mg capsules.
PlaceboDrug
Placebo matching to mavorixafor capsules
Primary outcomes
What the sponsor says the trial is designed to measure.
- Randomized Placebo-Controlled Period: Time (in Hours) Above Threshold-Absolute Neutrophil Count (TAT-ANC in hours) of ≥ 500 Cells/Microliter (µL) over a 24-hour periodTime frame: Time 0 (pre-dose, up to 15 minutes prior), 30, 60, and 90 min (each ± 5 min) and 2, 3, 4, 8, 12, 16, and 24 hours (each ± 15 min) post-dose at Baseline, Weeks 13, 26, 39, and 52
- Open-Label Period: Percentage of Participants With Adverse Events (AEs)Time frame: From Day 1 (end of randomized period) up to end of study (30 days post-treatment in open-label period [Week 56 of open-label period])
Locations
23 sites in 13 countries. Site status is shown where the registry gives one.
University of California San Diego Health/Rady Children's Hospital
San Diego, California
California Dermatology Institute
Thousand Oaks, California
University of Iowa
Iowa City, Iowa
Johns Hopkins University Medical Center
Baltimore, Maryland
University of Texas Southwestern Medical Center
Dallas, Texas
University of Washington Medical Center
Seattle, Washington
Wesley Hospital
Auchenflower, Queensland, Australia
Children's Health Queensland Hospital
South Brisbane, Queensland, Australia
Medical University of Vienna - Medizinische Universität Wien
Vienna, Austria
Aarhus University Hospital
Aarhus, Denmark
CHU Paris Est, Hôpital d'Enfants Armand-Trousseau
Paris, France
Hopital Necker-Enfants Malades
Paris, France
CHU de Lyon, Institut d'Hematologie et d'Oncologie Pediatrique
Lyon, Rhne, France
University of Debrecen, Affiliated Department of Infectology
Debrecen, Hajdú-Bihar, Hungary
HaEmek Medical Center
Afula, Israel
Università degli Studi di Brescia, Scienze Cliniche e Sperimentali
Brescia, Piazza Del Mercato, Italy
Emma Children's Hospital Academic Medical Center (AMC)
Amsterdam, Netherlands
Dmitry Rogachev National Research Center of Pediatric Hematology, Oncology and Immunology
Moscow, Russia
Academician I.P. Pavlov First Saint Petersburg State Medical University
Saint Pertersburg, Russia
Seoul National University Hospital, Children's Hospital
Seoul, South Korea
Hospital Sant Joan de Deu Barcelona
Barcelona, Esplugues de Llobregat, Spain
Hospital Universitario Virgen del Rocío
Seville, Sevilla, Spain
Cukurova University Faculty of Medicine
Sarıçam, Adana, Turkey (Türkiye)
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.